Failure of CDKN2A/B (INK4A/B–ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL
Open Access
- 1 June 2008
- journal article
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 22 (11) , 1411-1415
- https://doi.org/10.1101/gad.1673908
Abstract
Deletions of the CDKN2A/B tumor suppressor locus and of the IKAROS and PAX5 genes that promote B-lineage development occur frequently in lymphoid, but not myeloid leukemias initiated by the BCR-ABL tyrosine kinase. Why is this the case, and how do these genetic lesions contribute to an aggressive disease that fails to durably respond to targeted kinase inhibitors?Keywords
This publication has 38 references indexed in Scilit:
- BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of IkarosNature, 2008
- Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In VivoCancer Cell, 2007
- Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemiaGenes & Development, 2007
- Cellular Senescence in Cancer and AgingCell, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyBlood, 2006
- Cancer Stem Cells—Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem CellsCancer Research, 2006
- Regulation of the INK4b–ARF–INK4a tumour suppressor locus: all for one or one for allNature Reviews Molecular Cell Biology, 2006
- Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemiaProceedings of the National Academy of Sciences, 2006
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004